Bicycle Therapeutics Q3 net loss widens as R&D costs rise

Reuters

2025/10/30

Bicycle <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss widens as R&D costs rise

Overview

Bicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&D expenses
Company expects dose selection update for pivotal trial in Q1 2026
Strengthened leadership with new Board and Advisory Board appointments

Outlook

Bicycle Therapeutics expects financial runway into 2028
Company to provide Duravelo-2 trial update in 1Q 2026
Initial EphA2 human imaging data expected in 1H 2026

Result Drivers

INCREASED R&D EXPENSES - Higher R&D costs driven by zelenectide pevedotin development and other clinical programs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$59.10 mln
Q3 Basic EPS		-$0.85
Q3 Operating Expenses		$77.28 mln
Q3 Operating Incom		-$65.55 mln
Q3 Pretax Profit		-$58.89 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $25.50, about 67.9% above its October 29 closing price of $8.18

Press Release: ID:nBw8XBhDCa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579604110"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579604110\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579604110?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579604110","market":"us","top_or_hot":-1,"title":"Bicycle Therapeutics Q3 net loss widens as R&D costs rise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens as R&amp;D costs rise</title></head><body><p><span>Overview</span></p><ul><li><p>Bicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&amp;D expenses</p></li><li><p>Company expects dose selection update for pivotal trial in Q1 2026</p></li><li><p>Strengthened leadership with new Board and Advisory Board appointments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bicycle Therapeutics expects financial runway into 2028</p></li><li><p>Company to provide Duravelo-2 trial update in 1Q 2026</p></li><li><p>Initial EphA2 human imaging data expected in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Higher R&amp;D costs driven by zelenectide pevedotin development and other clinical programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$59.10 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.85</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$77.28 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Incom</p></td><td></td><td><p>-$65.55 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$58.89 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Bicycle Therapeutics <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $25.50, about 67.9% above its October 29 closing price of $8.18</p></li></ul><p>Press Release: <span>ID:nBw8XBhDCa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bicycle Therapeutics Q3 net loss widens as R&D costs rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBicycle Therapeutics Q3 net loss widens as R&D costs rise\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-30 19:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Bicycle <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens as R&amp;D costs rise</title></head><body><p><span>Overview</span></p><ul><li><p>Bicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&amp;D expenses</p></li><li><p>Company expects dose selection update for pivotal trial in Q1 2026</p></li><li><p>Strengthened leadership with new Board and Advisory Board appointments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bicycle Therapeutics expects financial runway into 2028</p></li><li><p>Company to provide Duravelo-2 trial update in 1Q 2026</p></li><li><p>Initial EphA2 human imaging data expected in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Higher R&amp;D costs driven by zelenectide pevedotin development and other clinical programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$59.10 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.85</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$77.28 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Incom</p></td><td></td><td><p>-$65.55 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$58.89 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Bicycle Therapeutics <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $25.50, about 67.9% above its October 29 closing price of $8.18</p></li></ul><p>Press Release: <span>ID:nBw8XBhDCa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL1N3WB0OF:1","article_id":"2579604110","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579604110","pubTimestamp":1761822777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bicycle Therapeutics Q3 net loss widens as R&D costs riseOverviewBicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&D expensesCompany expects dose selection update for pivotal trial in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCYC":"Bicycle Therapeutics Limited"},"translate_title":"随着研发成本上升，Bicycle Therapeutics第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCYC":0.9},"content_text":"Bicycle Therapeutics Q3 net loss widens as R&D costs riseOverviewBicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&D expensesCompany expects dose selection update for pivotal trial in Q1 2026Strengthened leadership with new Board and Advisory Board appointmentsOutlookBicycle Therapeutics expects financial runway into 2028Company to provide Duravelo-2 trial update in 1Q 2026Initial EphA2 human imaging data expected in 1H 2026Result DriversINCREASED R&D EXPENSES - Higher R&D costs driven by zelenectide pevedotin development and other clinical programsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$59.10 mlnQ3 Basic EPS-$0.85Q3 Operating Expenses$77.28 mlnQ3 Operating Incom-$65.55 mlnQ3 Pretax Profit-$58.89 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $25.50, about 67.9% above its October 29 closing price of $8.18Press Release: ID:nBw8XBhDCaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}